BACKGROUND: Recurrent treatment with intravitreal anti-VEGF (vascular endothelial growth factor) administration can in rare cases lead to secondary glaucoma that is difficult to adjust. The goal of this case series was to analyze the treatment results of the XEN® gel stent in combination with mitomycin C. METHODS: The long-term follow-up over a period of 18 months was evaluated for 3 eyes in 3 patients that underwent treatment with a XEN® gel stent in combination with mitomycin C as a surgical procedure to reduce intraocular pressure. RESULTS: The eyes had a baseline pressure of 21-31 mm Hg with 3-5 antiglaucoma medications following 15-25 intravitreal injections. In all 3 eyes a pressure drop of almost 50% to 9-14 mm Hg could be achieved after 18 months with complete discontinuation of all local and systemic medications to reduce intraocular pressure in 2 of the 3 eyes. In 1 eye a choroidal detachment occurred for 2 weeks postoperatively. In another eye a surgical revision of conjunctival penetration was carried out. In two eyes needling was necessary due to scarring. In 2 out of 3 eyes, further intravitreal treatment (9 and 13 respectively) was necessary due to the macular disease but no further increase in intraocular pressure occurred. CONCLUSION: The XEN® gel stent in combination with mitomycin C is a therapeutic option for difficult to adjust secondary glaucoma following intravitreal anti-VEGF therapy. A continuation of intravitreal anti-VEGF therapy did not lead to a recurrent increase of intraocular pressure.
BACKGROUND: Recurrent treatment with intravitreal anti-VEGF (vascular endothelial growth factor) administration can in rare cases lead to secondary glaucoma that is difficult to adjust. The goal of this case series was to analyze the treatment results of the XEN® gel stent in combination with mitomycin C. METHODS: The long-term follow-up over a period of 18 months was evaluated for 3 eyes in 3 patients that underwent treatment with a XEN® gel stent in combination with mitomycin C as a surgical procedure to reduce intraocular pressure. RESULTS: The eyes had a baseline pressure of 21-31 mm Hg with 3-5 antiglaucoma medications following 15-25 intravitreal injections. In all 3 eyes a pressure drop of almost 50% to 9-14 mm Hg could be achieved after 18 months with complete discontinuation of all local and systemic medications to reduce intraocular pressure in 2 of the 3 eyes. In 1 eye a choroidal detachment occurred for 2 weeks postoperatively. In another eye a surgical revision of conjunctival penetration was carried out. In two eyes needling was necessary due to scarring. In 2 out of 3 eyes, further intravitreal treatment (9 and 13 respectively) was necessary due to the macular disease but no further increase in intraocular pressure occurred. CONCLUSION: The XEN® gel stent in combination with mitomycin C is a therapeutic option for difficult to adjust secondary glaucoma following intravitreal anti-VEGF therapy. A continuation of intravitreal anti-VEGF therapy did not lead to a recurrent increase of intraocular pressure.
Authors: I Leleu; B Penaud; E Blumen-Ohana; T Rodallec; R Adam; O Laplace; J Akesbi; J-P Nordmann Journal: J Fr Ophtalmol Date: 2018-09-07 Impact factor: 0.818
Authors: Quan V Hoang; Angela J Tsuang; Rony Gelman; Luis S Mendonca; Kara E Della Torre; Jesse J Jung; K Bailey Freund Journal: Retina Date: 2013-01 Impact factor: 4.256
Authors: S Vo Kim; F Fajnkuchen; V Sarda; L Qu-Knafo; B Bodaghi; A Giocanti-Aurégan Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-08-22 Impact factor: 3.117
Authors: Nicolas A Yannuzzi; Samir N Patel; Kavita V Bhavsar; Fumitaka Sugiguchi; K Bailey Freund Journal: Am J Ophthalmol Date: 2014-05-06 Impact factor: 5.258
Authors: Thomas Wecker; Christoph Ehlken; Anima Bühler; Clemens Lange; Hansjürgen Agostini; Daniel Böhringer; Andreas Stahl Journal: Br J Ophthalmol Date: 2016-05-23 Impact factor: 4.638